CXCR6-transduced T cells for targeted tumor therapy

Patent metadata

Field	Value
Publication number	US-11723922-B2
Application number	US-201615768301-A
Country	US
Kind code	B2
Filing date	Oct 14, 2016
Priority date	Oct 16, 2015
Publication date	Aug 15, 2023
Grant date	Aug 15, 2023

Abstract

The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) γδ T cell(s) or (a) natural killer (NK) T cell(s) for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.

First claim

The invention claimed is:

1. A T cell expressing a chemokine receptor 6 (CXCR6) having the amino acid sequence of SEQ ID NO:2, which T cell is transduced with an expression vector encoding said CXCR6,
wherein said T cell has anti-tumoral specificity and/or wherein said T cell is co-transduced with a nucleic acid encoding a T cell receptor or a chimeric antigen receptor, said T cell receptor or said chimeric antigen receptor providing said T cell with specificity for a tumor antigen.

2. A pharmaceutical composition comprising the transduced T cell of claim 1 .

3. The transduced T cell of claim 1 , wherein the transduced T cell is a T cell originally obtained from the patient to be treated.

4. The transduced T cell of claim 1 , wherein the T cell is a T cell selected from the group consisting of a CD8+ T cell, CD4+ T cell, a γδ T cell and a natural killer (NK) T cell.

5. The transduced T cell of claim 1 , wherein said T cell is co-transduced with a nucleic acid encoding a chimeric antigen receptor, said chimeric antigen receptor providing said T cell with specificity for a tumor antigen.

6. The transduced T cell of claim 1 , wherein said vector comprises the nucleic acid sequence of SEQ ID NO: 1.

Assignees

• Univ Muenchen Ludwig Maximilians

Inventors

• Kobold Sebastian
• Endres Stefan
• Rapp Moritz
• Grassmann Simon

Classifications

• A61K40/4219

  Receptors for chemokines · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• C07K14/7158 Primary

  for chemokines · CPC title

• C12N5/0636

  T lymphocytes · CPC title

• A61K35/17 Primary

  Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title